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Role of genetics in prediction of coronary artery disease.
Andrey Yuabov
Introduction:
Coronary arteries disease (CAD) is a leading cause of death in United States and rest of
the world. It mostly involves atherogenic formation within the walls of the coronary arteries,
which in turn restricts the adequate perfusion to the heart muscle. This leads to myocardial
infarction and sudden death. In the past few decades the theories of coronary arteries disease
pathogenesis have changed. The facts reveal that the onset of the disease can develop as early as
childhood. The degree of the disease gradually progresses in stages and it is regarded as a
complex, ongoing inflammatory process that begins with initial endothelial dysfunction. There
are multiple risk factors that directly and indirectly impacts the development and progression of
CAD such as hypercholesterolemia, smoking, hypertension, diabetes, stress , high fat meals, lack
of exercise, alcohol abuse, obesity and recently chronic infections were added to the list as well.
Moreover, we realize now that coronary artery disease runs in the family and there are some risk
factors that can not be altered or controlled such as age, sex and heredity. We know that the firstdegree relatives of people who suffers from coronary artery disease at the early age are at much
greater risk that others. Coronary artery disease is considered to be highly complex
heterogeneous disease that results from blended effect of multiple genes. In recent years,
researchers have identified the involvement of about 400 genes that might contribute to or to
protect against development of disease.(Dzau and Liew 2007). Although, the definite
conformation that even half of those is actually involved is still a long way from determination.
The bigger question arises from all this information. Can we take an individual genomic profile
and translate it into something that’s clinically useful? Rather, than discuss all 400 genes that
have been implicated, this paper will focus on several of the best-understood genes in order to
find their practical application. Among them are disease-causing genes, susceptibility genes and
disease-linked genes. It is important to keep in mind that this situation is rapidly changing and
hopefully in future genetic approaches will shape the practice of medicine in fundamental ways.
Normal structure and physiology
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The heart functions as a pump that delivers blood to the rest of the body. It consists of the
three main layers: endocardium, myocardium and epicardium which surrounds by pericardium.
Just like all other organs it has its own blood supply which delivered via two coronary arteries
that branches of the aorta. The right coronary artery (RCA) lies in the coronary sulcus and
supplies blood to the right ventricle, right
atrium, and some portion of posterior wall of
the
left ventricle as well as sinoatrial (SA) and
atrioventricular (AV) node. The left coronary
artery
(LCA) immediately branches into the left
anterior descending artery (LAD) and the
circumflex artery (Cx). The LAD primarily
supplies blood to the wall of the left ventricle
and
ventricular septum as well as to the anterior
wall
of the right ventricle. The Cx encircles the heart
and
lies in the anterior interventricular sulcus and
supplies blood to left atrium, lateral wall of the
left
ventricle and partially supplies SA node and posterior wall of the left ventricle (Fig 1). Delivery
of blood to myocardium is complicated by compression of intramyocardial vessels during
systole, which results in the retrograde blood flow in coronary arteries during diastole. Therefore,
subendocardial layer of the myocardium is more susceptible to hypoperfusion because
ventricular diastolic pressure opposes the driving pressure for flow. Development of CAD will
further complicate myocardial perfusion.
Coronary arteries consist of three layers: the innermost tunica intima, tunica
media, and the outermost tunica adventitia. The tunica intima forms an inner lining of a artery
and is in direct contact with blood. It is comprised of single layer of squamous epithelial cells,
called endothelium that is embedded in an
extracellular matrix. The internal elastic lamina
Figure 1.coronary circularion
separates the tunica intima from the tunica media
(Fig 2
www.cvphysiology.com/Blood%20
).
Flow/BF001.htm

Figure 1. cross-sectional view of
coronary artery
www.chelationtherapyonline.com/article
s/p169.htm

Endothelial cells secret locally acting chemical mediators that influence the contractile state of
the overlying smooth muscle that play a major role in the control of the vascular tone. These
molecules include vasodilators such as prostacyclin, endothelial-derived relaxing and
hyperpolarizing factors (EDRF), (EDHF). It also produces vasoconstrictor substances, such as
endothelin and prostanoids. In addition, endothelial cells synthesize and secrete heparans and
growth factor that regulates smooth muscle cell proliferation. Endothelium remains healthy by
secreting different substances that prevent it from platelets aggregation or adhesion of other
molecules. The media is relatively thick layer comprised mainly of smooth muscle cells and
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elastic fibers. It’s primary role to control the diameter of the lumen by smooth muscle cell
contraction or relaxation. Tunica externa is the most outer layer and consists of elastic and
collagen fibers. It contains numerous nerve ending and tiny vessels that supply tissue of the cell
wall itself as well as connects the artery to the surrounding tissue. This layer separates from
media by network of elastic fibers, called external elastic lamina.
Pathophysiology of CAD Atherosclerosis is the major cause of CAD. Theories of the
pathophysiology of atherosclerosis underwent big changes over time. Few decades ago it was
looked as mostly disorder of lipid storage, and later it was considered to be disorder of lipid
metabolism. Further, CAD was looked as disease of the smooth muscle proliferation. With the
discovery of inflammatory cells and molecule in plaques led to conclusion that disease might be
inflammatory in nature. Current views on pathogenesis of atherosclerosis are as follows. The
development of an atherosclerotic plaque is a multi step process. The presence of risk factors for
CAD, such as hypercholesterolemia, cigarette smoking, hypertention, diabetes mellitus and shear
stress are associated with endothelial dysfunction. These conditions gradually damage healthy
and smooth lining of endothelium. This is the first step in development of atherosclerosis and it
results in increased permeability of endothelium (fig 3).
Figure (3)
Atherogenesis
www.vhn.ca/im
ages/atheroscle
rosistimeframe.
gif

Once the layer is damaged, the excess low density lipoproteins and other cellular waste product
can easily get into the inner layer of an artery wall. While entrapped low density lipoprotein is
progressively accumulates and undergo oxidation. This initiates inflammatory response and
stimulates smooth muscle cells proliferation. In response to invasion, endothelium and smooth
muscle cells release mediators to initiate recruitment of leukocytes, T-cells and monocytes into
the developing lesion. Furthermore, intralesional monocytes become macrophages. They eat and
digest large amounts of surrounding oxidized low density lipoprotein. As of the result of this
process, these lipid filled macrophages are becoming foam cells, due to their foamy appearance.
Together with T cells and monocytes, they form the bulk of “fatty streaks”. ”. The next stage in
development of atherosclerosis is a formation of “intermediate or fibrofatty lesion” which is
more complex in composition. The combination of fatty streaks growth and ongoing
inflammation, stimulate smooth muscle cells to multiply and migrate to an injury site. As these
cells become noncontractile and fibrous they migrate to the top of the atherosclerotic plaque,
forming a cap over it. These lesions might not be immediately harmful and may be viewed as
protective response to injury. As this plaque continues to grow, the coronary arteries gets thicker,
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harder and looses its elasticity. Calcium ions binding to the site of the plaque formation might
contribute to lack of elasticity as well. As plaque expands into the lumen of a coronary artery,
blood flow is greatly reduced through that artery. At this stage physical symptoms such as chest
pains and shortness of breath may occur which associates with angina pectoris. However, it is the
physical disruption of the plaque exhibits an acute coronary event such as myocardial infarction.
The rupture of the plaque usually occurs due to increased pressure in a narrow artery. It might
cause the complete occlusion due to blood clot formation cascade and manifest MI or sudden
death.
Genomic approach to CAD
The biggest challenge for scientists of a new era of genetics is to identify the genes and
gene expression changes that are responsible for pathological process of CAD. Two main
projects: human genome project and international hapmap project provided a crucial data for
genetic analysis in a complex heterogenic disease such as atherosclerosis and coronary artery
disease. To study such as complex diseases, scientists recently have been using two general
categories of study designs such as association studies and linkage studies. In Linkage studies,
the goal is to identify the inheritance of the disease in large families throughout few generations.
It is possible if we are able to identify single nucleotide polymorphism (SNP) on the fragment of
the chromosome that is inherited by family who is affected by a disease but not those who is
disease free. Furthermore in this design, we concentrate on identifying the gene variation of our
interest after narrowing down the section of a chromosome. This methodology is found to be
helpful especially in identifying diseased genes that inherited in a Mendelian fashion. Gene
disease associated study was introduced in 1996. It is designed to identify genetic variation of
available genome in associations with specific trait or disease of interest. Two independent
groups are usually participate in these studies. Those groups are, “cases” which are those
individuals who has been diagnosed with a disease and “control” are those who are similar
people within same parameters that are disease free. After carefully calculated results, if
frequencies of genetic variation are greater in individuals who are affected by a disease then it
said to be associated with a disease. Positive association cannot be interpreted as causation, but
only statistical association for the most part. Both of these methods have their advantages and
disadvantages just like any other studies.
Throughout years of genetic study, molecular biologists have identified several diseasecausing genes for disorders in lipid metabolism. They are directly related to development of
coronary artery disease. In order to understand dyslipidemia disorders, it’s important to
understand the physiology of lipid metabolism. Lipids are hydrophobic and therefore have to be
transported by lipoproteins in blood. Different lipoproteins have variety of integrated and
peripheral apoproteins that perform a different functions such as structural integrity, receptor
binding, and enzyme activation. Lipoproteins are categorized by their density of protein content.
They divide into two major groups high density lipoproteins (HDL) and non-high density
lipoproteins. Non-high density lipoproteins are further subdivided into chylomicrons, very-low
density lipoprotein, intermediate density lipoproteins and low-density lipoproteins. They
transport lipids from sites of absorption or synthesis to sites of their utilization. High-density
lipoproteins are considered as “good cholesterol”. They are responsible for transport of excess
lipids in circulation back to the liver.
For example Apoprotein B mostly found on non-high density lipoprotein and involves
in assembly and packaging of ingested triglycerides and cholesterol into non-high density
lipoproteins. Apoprotein E involves in receptor binding to hepatocytes via (LDL receptor).
57

Through this mechanism, liver uptakes the necessary lipid contents from non-high density
lipoprotein. Apoprotein C binds to adipocytes and skeletal muscle cell via lipoprotein lipase,
which acts as the receptor to facilitate lipid absorption.
Disease-causing genes have been identified for disorders in lipid metabolism such as
familial hypercholesterolemia, familial defective Apolipoprotein B, Apolipoprotein A
deficiency, Tangier disease, Autosomal recessive hypercholesterolemia, Sitosterolemia ect.
Familial hypercholesterolemia (LDL)receptor
Familial hypercholesterolemia is an autosomal dominant disease defined by the presence
of mutation in the low-density lipoprotein receptor gene. It characterized by severely elevated
plasma level of low density lipoprotein (Saint-Jore B et al., 2000) Heterozygouse familial
hypercholesterolemia is the most prevalent and affect about 1 in 500 people. Affected
heterozygous individual exhibit plasma cholesterol levels in the range of 300-400 mg/dl.
Clinically, patients develop severe atherosclerosis involving multiple vascular territories but
especially in coronary arteries. This leads to premature coronary atherosclerosis in fourth decade
of life and often requiring bypass surgery early in life. Familial hypercholesterolemia patients
were found to have one copy of mutated low density lipoprotein gene, which normally is located
on chromosome 19p13. A variety of point, deletion and splice mutation have been described.
Effect of this mutation leads to loss of its function. The mutant low density lipoprotein receptor
has reduced affinity for removal of apolipoprotein B and E from the circulation. (Marian
Ali,2000) Because Familial hypercholesterolemia is not only relatively common and associated
with a high risk of early coronary artery disease but is treatable with LDL-C-lowering strategies,
this genetic disorder meets the World Health Organization criteria for systematic screening. It
has been estimated that familial hypercholesterolemia is properly diagnosed in only 15% of
affected Canadians and as many as 30% of the patients do not survive their first myocardial
infarction. Therefore, early detection of the disease has the potential to save life and prevent
morbidities (Yuan et al.,2006)
Apolipoproteins are important components of lipoprotein particles. Current data shows
that measurements of various apoliportroteins may help to predict the risks of coronary artery
disease ( Walldius & Jungner, 2004).Their involvement in synthesis and metabolism of
lipoproteins are gradually being defined. In addition to stabilizing lipoprotein structure, some of
lipoproteins act as ligands to tissue receptors, while others activate or inhibit enzymes involved
in metabolic steps in circulation or tissues.
Apolipoprotein A deficiency.
Apolipoprotein A has two major forms A1 and A2. Apolipoprotein A1 is associated with high
density lipoprotein cholesterol, and may be largely responsible for determining the plasma level
of it. In addition apolipoprotein A1is the ligand for ATP-binding cassette protein and hence is
involved in the docking procedure by which excess cholesterol in peripheral cells is externalized
to high density liporprotein (Walldus & Jungner,2004). Its been reported that deficiency of
apolipoprotein A1and low levels of high density liporprotein cholesterol were significantly
related to an increased risk of cardiac mortality in patients with coronary artery disease(Walldus
& Jungner,2004). Gene coding for apolipoprotein A1is located on the long arm of chromosome
11. Two polymorphism of apolipoprotein A1gene namely G to A substitution at -75bp of
transcription start site and C to T substitution at +83 bp have been implicated in susceptibility to
coronary artery disease and shown to influence plasma lipid levels (Taranjit et al.,2008) Many
studies are controversial about the effect of particular gene polymorphism on pathogenesis of
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atherosclerosis and coronary artery disease, but in combination with other polymorphic variants
may be better predictor of disease risk in future.
Familial Defective Apolipoprotein B
Plasma lipoproteins are important determinants of atherosclerosis. Apolipoprotein B is a
large amphipathic glycoprotein that exists in two forms and plays an important role in lipid
metabolism. Both forms are produced by the same apolipoprotein gene: apolipoprotein b-48,
which is required for chylomicron production in the small intestine and apolipoprotein; b-100,
which is required for very low density lipoprotein production in the liver. In addition,
apolipoprotein b-100 is the ligand for low density lipoprotein-receptor-mediated endocytosis of
low density lipoprotein particles.(Whilfield et al.,2004) Mutation in apolipoprotein b-100 is
characterized by increased plasma low density lipoproteins and very low density lipoprotein
levels and has clinical features of hypercholesterolemia and premature coronary artery
disease(Marian.Ali.2000). Familial defective apolipoprotein b-100 is a second relatively
common cause of severe autosomal dominant hypercholesterolemia (Dzau. 2007). It is relatively
common, with estimated frequency of 1 out of 500 in normal population and clinically not
possible to distinguished from heterozygous familial hypercholesterolemia (Whilfield et
al.,2004). The most common mutation is R3500Q which involves in substitution of a glutamine
for arginine at the position 3500 (Whilfield et al.,2004). Other point mutation, R3500W and
R3500C are rare cause of familial defective apolipoprotein b-100 (Real et al.,2003). Low density
lipoproteins of affected individual will have a 90% decrease in affinity for low density
lipoprotein receptor and low density lipoproteins clearance will be markedly impaired. Therefore
routine screening is feasible and should be performed not only in subjects with clinical
phenotypes but also in asymptomatic subjects with elevated low density lipoprotein
levels.[Ali.2000] Treatment is similar to that of familial hypercholesterolemia with reliance on
statin therapy, which both decrease very low density lipoprotein production and enhances
clearance of very low density lipoprotein remnants[Dzau.2007]
Other mutations of Apolipoprotein b-100 may cause familial hypobetalipoprotenimia,
which is characterized by hypocholesterolemia and resistance to atherosclerosis and coronary
artery disease (Whitfield et al 2004).
Autosomal recessive hypercholesterolemia is caused by mutation in a putative adaptor
receptor protein called ARH, that function in the internalization of low density lipoprotein
receptor and cargo. This recessive disorder is characterized by severe hypercholesterolemia,
xanthomatosis and premature coronary artery disease (Arca et al., 2002). Autosomal recessive
hypercholesterolemia did not associated with the low density lipoprotein receptor or
apoliporpotein b genes and exhibited an autosomal recessive inheritance, with the parents of the
affected subjects having normal low density lipoprotein cholesterol values [Dzau.2007].
Interestingly, the function of low density lipoprotein receptor is near to normal in their cultured
fibroblast but is impaired in lymphocytes, macrophages and hepatocytes. Low density
lipoprotein receptor protein is present in these cells within normal limits but dispersed unevenly
with most of the receptor residing on the plasma membrane, where it binds to low density
lipoprotein but fails to internalize and degrade its cargo [Dzau.2007]. This specific disorder is
rare and prevalent in Sardinia, Italy. Two ARH mutation were present in all 17 unrelated
Sardinians families with ARH: a frameshift mutation (C432insA) in exon 4( ARH1) and
nonsense mutation (C65G->A) in exon 1(ARH2) (Arca et al., 2002) . Screening of the coding
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regions of ARH with similar phenotype in other random parts of the world revealed that only
four out of 40 of them were positive for ARH1 mutation and all happened to be Italian.
Low circulating serum levels of high density lipoprotein cholesterol seem to be a frequent
lipoprotein disorder in coronary artery disease and can be caused by either genetic or lifestyle
factors. Many gene abnormalities can cause this lipid disorder.
Tangier disease is a rare disorder of lipid metabolism, characterized by extremely low
levels of high density lipoprotein cholesterol. It is caused by mutation in the adenosine
triphosphate-binding cassette transporter A1 (ABCA 1), also known as the cholesterol efflux
regulatory protein (Kolovou et al.,2006). ABCA1 is a member of ATP-binding cassette
transporter family. These integral proteins use ATP as a source of energy to transport variety of
molecules including ions, vitamins, lipids, peptides proteins and number of hydrophobic
compounds across intracellular and plasma membranes (Kolovou et al.,2006). Complete loss of
ABCA1 function leads to severely decreased cellular cholesterol efflux and cholesterol ester
accumulation in macrophages and other cells of the reticuloendothelial systems (Rust et
al.,1999). Due to impaired ability to transport cholesterol out of the peripheral cells, it
accumulates in body tissues. Therefore clinically, Tangier disease patients present with
hepatosplenomegaly, enlarged tonsils, neurapathy and most important in our case atherosclerotic
lesions. Studies suggested that carriers of defective adenosine triphosphate–binding cassette
transporter A1 bear a moderately increased risk for coronary artery disease.
Sitosterolemia is a rare autosomal recessive disorder. It characterizes by markedly increased
intestinal absorption of all sterols including cholesterol, shellfish and plant sterols and impaired
resecretion of those sterols into bile. Affected individual have expanded body pools of
cholesterol and very elevated plant-sterol levels. Affected individual will frequently develop
accelerated atherosclerosis and premature coronary artery disease (Lu et al.,2001) In the studies,
it has been mapped that this condition results from over 25 mutation in either ABCG5 or ABCG8
genes which located on chromosome 2 in band 2p21. These genes encode for adenosine
triphosphate-binding cassette transporter protein (ABC) transporters, steroline-1 and steroline -2.
Their functions are to limit intestinal absorption and stimulate excretion of noncholesterol sterols
by liver into bile. Mutation of these transporters predispose to sterol accumulation and early
artherosclerosis. Sitosterolemia can clinically present similar to homozygous familiar
hypercholesterolemia in terms of elevated LDL-cholesterol especially in childhood around 300
mg/dl or 8 mmol/l. Therefore, it a possibility that sitosterolemia is frequently misdiagnosed with
hyperlipidemia.
Although, all mentioned above lipid metabolism disorders are rare, they are high risk
factors and directly related to incidence of coronary artery disease. Studies of these disorders
gave researches a better understanding of lipoprotein and cholesterol metabolism. Whether
hypercholesterolemia is caused by mutation in one gene or cumulative effect of several genes
defects, early diagnosis is essential to start appropriate therapy. Most notable was development
of Statins drugs which is a class of medications that was developed to lower plasma low density
lipoprotein cholesterol levels.
MEF2A

60

Recently, the first non-lipid related disease causing gene was identified and proposed to be
responsible for an autosomal dominant form of coronary artery disease (adCAD). However,
when association is detected, it is still difficult to prove direct causality. False positive
association may arise due to differences in ethnicity, age or sex [Dzau, 2007]. Several studies
were performed to identify the role of human myocyte enhancer factor-2A (MEF2A) and its
mutation in early coronary artery disease development .MEF2A is a protein that is coded by
MEF2A gene which is located on chromosome 15q26. The seven-amino acid deletion of the
human transcriptional myocyte enhancer factor-2A was reported to be a functional mutation. It
disrupted nuclear localization of MEF2A, reduced MEF2A-medieted transcription activation. In
addition it abolished synergistic activation by MEF2A and by transcriptional factor GATAbinding protein which involved in cell growth, with which MEF2A interact to regulate the
expression of the downstream target genes, by dominant –negative mechanism (Wang et
al.,2003). One study was dealing with large family with 13 patients who had an autosomal
dominant patterns of CAD. Nine of 13 patients later developed acute myocardial infarction.
Further genome wide association study linked data to chromosome 15q26. MEF2A also
demonstrate its relevance to expression of coronary arteries endothelium (Wang et al.,2003).
Another independent case-control studies was performed from 2003 to 2007 involving 726
individuals in China (Han et al.,2007). The results of that study suggested the disease-causing
relationship between MEF2A and coronary artery disease. In subsequent study, Weng et al who
report sequencing MEF2A in 300 patients with premature coronary artery disease and control,
only 1 CAD patient was reported to have the mutation that wasn’t found in the control group
(Altshuler & Hirschhorn, 2005). Also another study in large Irish population showed no
association between variation in the MEF2A gene and coronary artery disease (Horan et
al.,2006).However, the absence of CAD in a control group wasn’t confirmed by angiography. As
science progresses it is becoming much easier to collect data but it also causes many controversy
in its analysis. MEF2A plays an important role in cardiovascular biology, but its genetic
variation contribution to pathophysiology in CAD should be further validated in order to make it
the criteria for genetic testing for CAD.
Susceptability genes are those that increase or decrease the risk of developing disease and in
combination with environmental factors and other genetic factors may contribute to pathogenesis
of a disease. These genes might have less predictive values for developing a disease, but
contribute a lot to understanding of pathophysiology process.
eNOS gene.
Nitric oxide (NO) is gas and is identified as endothelium derived relaxant factor. NO is
synthesized from substrate L-arginine by endothelial cell nitric oxide synthase (eNOS) which
encoded by nitric oxide synthase 3 gene (NOS3) that is located on 26-exon on chromosome 7.
NO plays a few important roles in healthy endothelium such as regulation of vascular tone in
coronary arteries, prevents leukocytes adhesion and platelets aggregation and inhibits vascular
smooth muscle migration and proliferation. Biochemical and/or physical shear stress damages
endothelium and impairs production of mediator such as nitric oxide. This might lead to
vasoconstriction, loss of elasticity and promote platelets activation. Indirectly decrease in nitric
oxide activity affect conditions such as hypertension and hypercholesterolemia which predispose
to atherosclerosis [Dzau.2007]. Few clinical studies indicated relationship between different
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eNOS gene polymorphism and atherosclerosis development. The most commonly studied variant
is Glu298Asp which is conversion of glutamate to aspartate at the position 298 that results from
G894T substitution within exon 7. In English study sample Glu298T variance has been reported
to be associated with atherosclerotic coronary arteries. The mechanism is unknown but by
altering mature protein activity can affect enzyme activity and decreased local nitric oxide
synthesis. As a result of case-control study involve Iranian population (Salimi et al., 2006), we
observed that the genotype frequencies differ from allele frequencies significantly between
control and CAD patients. However, controversy brought up by other small studies that do not
support these findings. Therefore the relevance of this data remains unclear. It might be because
of subjects were picked from different ethnicity and genetic background. Further larger studies
are needed in order to prove major effect of Glu298Asp polymorphism on disease development
but for now it can be considered as indirect genetic marker associated with the disease.
TNF-alpha
Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine that plays a role in
pathogenesis of CAD. It was localized in atherosclerotic plaque in pathological studies.
Macrophage derived TNF-alpha has important pro-inflamatory autocrine and paracrine effect.
Stimulation of the cells by TNF-alpha, activate the cascade of events that lead to upregulation of
various adhetion molecules. Overall contribution of TNF-alpha believed to be activation of
influx of additional inflammatory cells and involvement in endothelial dysfunction (Dzau 2007).
TNF-alpha has two receptors through which it exerts its effect TNFR1 and TNFR2.
Polymorphisms in TNF-alpha and TNF receptor genes are hypothesized to affect secretion of
this cytokine and relate to presence or severity of CAD. To investigate this matter scientist
conducted a study 259 patients with angiographiclly confirmed CAD and control group (Allen et
al., 2001). As a result of the statistical analysis no significant differences were found between
polymorphism frequencies. Another European study was performed to investigate association of
TNF-alpha gene polymorphism and its relationship with CAD via polymerase chain reactionsingle-strand confirmation polymorphism and sequencing (Herrman et al.,1998). Although,
TNF-alpha gene polymorphism have been associated with number of inflammatory diseases it is
unlikely to contribute to development of CAD
Diseased-linked genes are those genes whose expression is linked or connected to the disease but
the cause and effect relationship is not established. They might serve as biomarkers for the
disease. A big chunk of genes were newly identified as disease-linked genes for CAD. The most
studied include intracellular adhesion molecules-2, E-selectine gene, ect. The reason for interest
in studying disease-linked genes is the fact that about half of the patients who are diagnosed with
CAD do not have traditionally established risk factors. Therefore, the search for other
biomarkers was proposed in order to help identify individuals who might be at risk.
Cellular adhesion molecules.
Cell adhesion molecules (CAMs) are transmembrane proteins that involve in binding of cells
with other cells or extracellular matrix. In healthy endothelium, expression of adhesion
molecules is very limited. In diseased coronary artery, transendothelial T-cells and monocytes
migration are mediated by these molecules (figure4) Transendothelial migration.
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One of
the CAMs category belong to Immunoglobulin superfamily. They are intracellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Animal and human
studies earlier show that overexpression of adhesion molecules and endothelial cell activation
causes accumulation of leukocytes in coronary tunica intima. According to latest reports,
expressions of cellular adhesion molecules is stimulated by cytokins such as interleukin-1,
tumour necrosis factor (TNF) and interferons-gamma (INF) (Ohta et al., 1999) Furthermore, the
increased expression of cellular adhesion molecules in atherosclerosis shows in early stages of
atherosclerotic development which presented by fatty streaks in inner layer of an artery as well
as the latest fibro-fatty lesions. Linkage of levels of ICAM-1 and VCAM-1 to coronary artery
disease that was established by study and can be considered as an independent risk predictor
(Hajilooi et al.,2003).Although, genetic aspect of these molecules remain poorly known, recent
multi-ethnic study was conducted to investigate relationship of 12/ICAM-1 and 7/VCAM-1
single nucleotide polymorphism (SNP) and coronary artery calcium and ICAM-1 SNP and
circulating levels of soluble ICAM-1. It showed no significant association of ICAM-1 and
VCAM-1 and coronary artery calcium in any ethnic groups, but polymorphism in ICAM-1
showed significant association with soluble ICAM-1 levels and was identified as a marker for
atherosclerosis (Bielinski et al ., 2008).
Other family of cell adhesion molecules consists of E-selectin and P-selectin. Both of
them suggested to play an important role in early and advance stages of coronary arthrosclerosis
from earlier double-knockout mouse experiment. P-selectine is important in the transient
attachment of leucocytes to endothelial cells and platelets (Carter et al., 2003). When endothelial
cells get activated via mediators such as histamine and thrombin in inflammatory process, Pselectine translocates from internal to endothelial cell surface. Just like prior mentioned cell
adhesion molecules, P-selectine also contributes to development of atherosclerosis by facilitating
adhesion of leukocytes to injured endothelium and platelets. Soluble P-selectins were found in
plasma in multiple conditions including heart disease. Number of polymorphism has been
identified in gene encoding P-selectin. THR715Pro polymorphism for example was reported to
be associated with myocardial infarction in previous studies. In 2003 the study was performed
that compared levels of soluble P-selectin in 249 individuals with CAD and 252 healthy control
group and investigated the relationship between polymorphism of P-selectin and circulated
soluble P-selectin levels and cardiovascular risk (Carter et al., 2003). It showed that levels of
soluble P-selectin were higher in affected individuals than control group after adjustment for age
sex and smoking status. Moreover, no significant association was found between P-selectin
polymorphism in CAD affected patients and healthy control group. This study suggested that the
relationship between Thr715Pro polymorphism and levels of soluble P-selectins exist but its
mechanism is still unclear.
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E-selectin also involved in adhesion of leukocytes to activated endothelium. Mutation
of E-selectin gene, due to G to T mutation (G98T) in untranslated region of exon 2, was found to
be significantly higher in frequency in patients with CAD than control group and thus suggests
association with premature coronary artery disease (Zheng et al.,2001).Even after adjustment for
other multifactor, mutation of G98T may be an independent risk factor for premature CAD.
Another study was performed in 2006 within Saudi Arab population. It attempted to investigate
amino acid change from serine to arginine at codon 128 (S128R), which corresponds toA>C
nucleotide change at the position 561 (A561C), in the epidermal growth factor-like domain of
the E-selectin gene that was previously implicated in pathogenesis of CAD in few ethnic groups
(Abu-Amero et al., 2006). The frequency of mutation in 128r allele was found to be much higher
in patients with CAD than control group, but lost association with adjustment for other CAD risk
factors. The most recent study that investigated Association of E-selectin gene (S128R)
polymorphism in patients with CAD within Indian population was consisted with previous
findings. It revealed the increased frequency of E-selectin polymorphism in CAD patients but its
interaction with other risk factors showed that in fact the significant determinant of coronary
artery disease were presents of diabetes, hypertension, smoking habit, elevated serum
triglycerides and low HDL level.
The involvement of cell adhesion molecules was established to play an important role in
development of atherosclerosis. Overall studies suggest that neither the measurements of soluble
adhesion molecules, nor screening for their gene polymorphisms cannot be an independent
predictor of CAD. It may only offer some additional marker of atherosclerosis but cannot go
beyond the assessment of conventional coronary artery disease risk factors.
Conclusion:
Throughout last decade significant advances in genetic studies were made which gave us a fair
insight on pathogenesis of coronary artery disease. It no longer viewed as a simply degenerative
disease or gradually accumulating lipid disease. Current views regard CAD as complex disease
that involved in active process of alteration in cell intercommunication and cell signaling. At this
point in time we can only speculate on assumed biological role of genetic polymorphisms that
has been identified in relationship with CAD. Field in genetic studies is promising and expects to
accelerate as future studies will focus on identifying new genetic polymorphism in connection to
CAD. However, at this time coronary artery disease can’t be simply diagnosed through genetic
testing, but can only look for variants that increase the risk of developing it. Prediction of CAD
via genetic polymorphism may eventually lead to clinical utilization, but now only physician can
diagnose the disease based on a medical history, family history, risk factors and the results of
medical tests. Genetic testing can not clearly tell if disease is going to develop or not, but if
certain genetic markers are present, it may help us to modify our estimated risk of developing it.
When considered genetics along with other individual’s information including other risk factors
may help individual to reduce the risks that we can control such as lifestyle, diet and exercise.
Moreover, if clinician knows about increased genetic predispositions, they may stronger
recommend lifestyle changes. In addition, high index of suspicion might result in early
diagnostic application and close monitoring of patient with marked genetic polymorphism by
their doctors. Currently a few of screening tests are available for asymptomatic individuals who
are at risk for premature atherosclerosis and CAD such as computed tomography, ultrasound ect.
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Hopefully in near future genetic studies will lead us to revolutionary changes in further
understanding, ability to diagnose, prevent and treat the wold’s biggest killer.
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